Obiri-Yeboah Derrick, Soni Pranay, Oyem Precious C, Almeida João Paulo, Murayi Roger, Recinos Pablo F, Kshettry Varun R
Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA; Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
World Neurosurg. 2023 Sep;177:e593-e599. doi: 10.1016/j.wneu.2023.06.100. Epub 2023 Jun 28.
To characterize and classify the location of recurrence in surgically resected World Health Organization (WHO) grade 2 intracranial meningiomas that did not receive adjuvant radiation and compare the recurrence pattern of those who underwent gross total resection (GTR) versus subtotal resection (STR).
We performed a retrospective review of patients who underwent surgical resection of a newly diagnosed WHO grade 2 meningioma at our institution between 1996 and 2019. Patients who were observed postoperatively without adjuvant radiation and subsequently developed a recurrence were included in the study. All patients who received adjuvant therapy were excluded. Recurrence was defined as any evidence of radiographic progression on postoperative surveillance magnetic resonance imaging. Location of recurrence was categorized as follows: 1) central-growth observed inside the area of the previously resected tumor more than 1 cm inside the original tumor margin; 2) marginal-growth observed within 1 cm (inside or outside) of the original tumor margin; and 3) remote-growth observed >1 cm outside the original tumor margin. Patterns of recurrence were evaluated by 2 observers after coregistering preoperative and postoperative magnetic resonance imaging, and any differences were reconciled by discussion.
A total of 22 patients matched the inclusion criteria. Twelve (55%) underwent GTR, and 10 (45%) underwent STR. In 12 patients in whom GTR was achieved, the mean preoperative tumor volume was 50.6 cm, with 5 (41.7%) in a skull base location. The average time to recurrence for these tumors was 22.7 months, with a mean recurrent tumor volume of 9.0 cm. Ten patients (83.3%) had central recurrence, 11 patients (91.7%) had marginal recurrence, and only 4 patients (33.3%) had remote recurrence. In 10 patients in whom STR was achieved, mean preoperative tumor volume was 44.8 cm, with 7 (70.0%) in a skull base location. The average time to recurrence for these tumors was 23.0 months, with a mean recurrent tumor volume of 21.8 cm. Of these 10 patients, 9 (90.0%) had central recurrence, all 10 (100.0%) had marginal recurrence, and only 4 (40.0%) patients had remote recurrence.
The present study evaluating patterns of recurrence for WHO grade 2 meningiomas after surgical resection (GTR or STR) showed that recurrence occurred centrally and/or at the original tumor margin, with only a few recurring >1 cm outside the original tumor margin. The results of this study suggest that treatment, whether initial surgical resection or adjuvant radiation, may benefit from including at least a 1-cm dural margin when safe, to optimize tumor control, but further clinical study is needed.
对未接受辅助放疗的世界卫生组织(WHO)2级颅内脑膜瘤手术切除后的复发部位进行特征描述和分类,并比较接受全切除(GTR)与次全切除(STR)患者的复发模式。
我们对1996年至2019年间在我院接受新诊断的WHO 2级脑膜瘤手术切除的患者进行了回顾性研究。术后未接受辅助放疗且随后出现复发的患者纳入本研究。所有接受辅助治疗的患者均被排除。复发定义为术后监测磁共振成像上任何影像学进展的证据。复发部位分类如下:1)中央生长,在先前切除肿瘤区域内、距原始肿瘤边缘1 cm以上观察到;2)边缘生长,在原始肿瘤边缘1 cm内(内侧或外侧)观察到;3)远处生长,在原始肿瘤边缘外>1 cm处观察到。在对术前和术后磁共振成像进行配准后,由2名观察者评估复发模式,任何差异通过讨论协调一致。
共有22例患者符合纳入标准。12例(55%)接受了GTR,10例(45%)接受了STR。在实现GTR的12例患者中,术前平均肿瘤体积为50.6 cm³,其中5例(41.7%)位于颅底。这些肿瘤的平均复发时间为22.7个月,复发肿瘤平均体积为9.0 cm³。10例患者(83.3%)有中央复发,11例患者(91.7%)有边缘复发,只有4例患者(33.3%)有远处复发。在实现STR的10例患者中,术前平均肿瘤体积为44.8 cm³,其中7例(70.0%)位于颅底。这些肿瘤的平均复发时间为23.0个月,复发肿瘤平均体积为21.8 cm³。在这10例患者中,9例(90.0%)有中央复发,所有10例(100.0%)有边缘复发,只有4例(40.0%)患者有远处复发。
本研究评估WHO 2级脑膜瘤手术切除(GTR或STR)后的复发模式显示,复发发生在中央和/或原始肿瘤边缘,只有少数在原始肿瘤边缘外>1 cm处复发。本研究结果表明,无论是初始手术切除还是辅助放疗,在安全的情况下,治疗可能受益于至少包含1 cm的硬脑膜边缘,以优化肿瘤控制,但需要进一步的临床研究。